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Introduction:
The Symposium began with a welcome and introduction from Kwok-Leung Cheung (Clinical
Associate Professor, University of Nottingham, Consultant Breast Surgeon, Royal Derby Hospital; UK
National Representative, International Society of Geriatric Oncology (SIOG), Symposium co-chair).
Mr Cheung began by extending a warm welcome to everyone to the East Midlands Conference
Centre and the University of Nottingham. He explained how the symposium, first started in 2010,
began in a very small room in the postgraduate education centre in City Hospital, Nottingham, with
only about 20-30 people in attendance. He was pleased to say that things had certainly moved on,
and the biennial symposium was now a multidisciplinary event with an emphasis on patient
perspectives, as a direct response to delegate feedback ranking patient sessions the best!
The symposium has CPD accreditation from the Royal Colleges and is basically the only event in the
country to be dedicated to a multidisciplinary focus on older women with primary breast cancer. Mr
Cheung was also happy to announce that since the event is under the auspices of SIOG, senior
members of SIOG will be speaking and presenting also.
Since the previous symposium, organisers have been giving a theme to the event, this year’s theme
being, ‘Putting personalised care into practice’, with an emphasis on the word ‘personalising’, since
it is well known that older women with primary breast cancer tend to be under- or over-treated
sometimes due to a lack of knowledge and other times due to over-enthusiasm or failure to include
them in clinical trials.
Also based on requests and feedback from previous conferences, Mr Cheung explained the addition
of a ‘students and patient advocates’ category at registration for the conference to encourage their
attendance.
The speaker list went beyond just oncological representations of surgeons and oncologists, including
an epidemiologist and a geriatrician from the previous symposium and in the 2015 event, the
geriatrician being particularly inspiring – especially for the UK delegates, since it’s not really standard
practice in the UK to include a geriatrician in the care of older women with primary breast cancer.
For the first time, there was a geriatric oncology nurse in the faculty – Mr Cheung termed this a ‘new
breed’ or ‘new concept’ to the UK, since although we have dedicated specialist nurses to specific
tumor sites, for example, breast care nurses, colorectal care nurses and so on, geriatric oncology
nurses are almost unheard of in this country.
In addition to a presentation on the topic of breast reconstruction in older women, to be delivered
during the symposium by a distinguished plastic and reconstructive surgeon, oral presentations were
also added to the program so that speakers could share their specific experiences. Furthermore, the
organising committee this year was expanded to include a surgical trainee.
The symposium abstracts and program has now been published in Future Oncology as an online
supplement [1] and the slides from the presentation are available on the symposium website [2].
Mr Cheung ended his introduction by thanking the sponsors of the event and encouraging delegates
to visit the stands during the break times and also to take time to look at the poster displays. He
encouraged people to join SIOG and directed them to the SIOG website for further information [3].
Session 1: Local and systemic therapies
The first session on ‘Local and systemic therapies’ was chaired by David Morgan (symposium co-
chair) and consisted of two presentations followed by a discussion session.
Dr Morgan began by also extending a welcome to everyone and was happy to say that he believed it
was one of the best turnouts since the symposium first began. He explained that in this first session,
they would be focussing on nonsurgical treatments – chemotherapy and radiation. One of the
‘problems’ with older patients is finding the right balance, so as not to under- or over-treat them.
Older patients by definition are more likely to suffer from diseases associated with age, and so frailty
as a general concept afflicts older patients more often than younger ones, therefore it is important
to find the correct balance – requiring more ‘personalisation’, personalisation being the key word for
today.
Selecting for chemotherapy – the use of genomics
The first talk in the session was given by Etienne Brain, Medical Oncologist at the Institut Curie in
France and also the Immediate Past President of SIOG, on the topic of ‘Selecting for chemotherapy –
the use of genomics’.
Dr Brain explained that although there have been great strides in the past decade in cancer
management in general, this has not benefitted the entire population, with older persons deriving
less benefit overall. The main dilemma faced when approaching any cancer in the older patient is
ageism – when you decide not to treat as you consider the patient is too old – referred to as
‘therapeutic nihilism’, and the opposite also can be true – ‘blind therapeutic enthusiasm’ – the use
of new treatment innovations bringing futile benefits with potential and uncontrolled side effects.
The stark differences in the biology of breast cancer was displayed on one slide [4,5]. According to
standard pathology reports, more luminal cases are seen in older women; on the molecular levels it
is apparent that less aggressive or basal-type cases are also seen in older women. Dr Brain stressed
that the difference actually appears not above 70 or 75 years of age, but rather much earlier, after a
postmenopausal setting.
Quite often therefore, these patients are undertreated and it happens on a very regular basis and
delegates were shown a graph demonstrating that the use of chemotherapy for node positive cases
(oestrogen receptor positive (ER+) N+ stage I/II breast cancer) decreases dramatically according to
age [6], mirroring the fear regarding side effects of chemotherapy, leading the physician to not take
the risk of delivering such treatment in the adjuvant setting. Underusing can lead to under-
treatment and in turn lead to a worse prognosis in these patients. From the same series and others
[6, 7] we were shown that breast cancer mortality increases by 20-30% in older patients compared
to their younger counterparts. It is important to note that mortality due to other causes increased
even more with age therefore a proper balance is required in the decision making regarding the
treatment process.
The converse to this is over-treatment – a sizeable proportion of older patients with operable breast
cancer die of non-cancer-related causes and therefore absolute benefit of treatments is lower. This
presents the main challenge when making these kinds of decisions. Adjuvant chemotherapy can
work irrespective of age and the difference arises in the side-effects and mortality rate being far
higher than what you see in younger adults [8]. When you look at big series with standard pathologic
characteristics, chemotherapy is mostly useful in ER- cases, [9,10], demonstrating that biology drives
the potential benefit of preventative treatment delivered.
Algorithms used to make decisions in the adjuvant setting are very inadequate and some have been
shown to be very badly developed for the older population. For example, ‘Adjuvant! Online’ is the
most achieved tool that is used in clinical practice, however, it is not accurate in older patients, nor is
it accurate in very young patients as it was developed in a standard adult population. ‘Predict’ is
another algorithm based on standard characteristics for the tumour, but predicts only for overall
survival not taking into account comorbidities and does not give any information on the risk of
relapse very well [11, 12].
Gene expression profiling (GEP) was developed since the early 2000s to identify prognosis and also
to identify patients requiring chemotherapy. The other pending question that came up from this was
how we can then avoid chemotherapy in some cases. All this was for the development of a better
individual risk stratification [13].
There are around 6 different tools available – some still in development, and all based on the
quantification of nucleic acid using different techniques. They do not all provide the same
information and have been developed in specific settings. These tools provide the continuous
variable or sometimes they dichotomise the population. A very important point stressed to us at this
point was that some tools are centralised in terms of determination while others can be performed
in a decentralised way. Furthermore, it should be noted that most of the trials did not include
women of 65+/70+ years of age.
Dr Brain went on to explain a few tools in detail. MammaPrint brings some prognostic information to
the table, allowing the de-escalation of the indication of chemotherapy. This tool was investigated in
the MINDACT program [14] and since none of the patients were older than 70 years of age, it gives a
skewed picture. MammaPrint provides information on the risk of distant recurrence at 5 years
without any treatment and this gives general results. How this can be extrapolated or utilised in the
older population remains questionable.
Another tool, OncotypeDX is different. This tool assesses the risk of distant recurrence at a)10 years
with the use of tamoxifen for 5 years in node negative patients and b) 5 years with the use of
tamoxifen for 5 years in node positive patients. Evaluation can therefore be confusing since the end
points and conditions are different. However, it does give personal results and that is an important
difference compared with MammaPrint and it has been investigated specifically in the older
population, based on a large data set derived with collaboration with the NCI and Genomic Health,
presented by S Shak at the last ESMO conference [15]. The work specifically focussed on the use of
the tool on node negative, HR+, HER2- cases and looked at the use of this innovation in older
populations, selecting almost 250,000 cases. Some of these cases were tested with the recurrence
score and others had not been. Looking at the partition between the 70+ and <70 year old patients,
there was about 3 times less testing of and use of recurrence score in the older patients.
Chemotherapy use was lower in patients ≥70 years of age tested or untested. 
As Dr Brain explained, what was important is that the use of the recurrence score according to age
shows that above or below 70 years of age, it provides some prognostic information above a
recurrence score of 18. Recurrence score predicts breast cancer specific mortality in both age
groups. Higher other-cause mortality was observed in older patients and notably, 5-year breast
cancer specific mortality is relatively high in untested patients of all ages, therefore deserving further
study.
Dr Brain explained MammaPrint used in ASTER 70s [16], an ongoing study, with about 2000 patients
above 70 years of age in the adjuvant setting after chemotherapy or after relapse in very specific
settings.
When all these signatures are compared, Dr Brain explained that many overlaps can be seen. A
prospective study was conducted [17] that assessed the value of different signatures and this
showed that all brought some kind of prognostic information but the overlap in the genes assessed
is not complete and there are some exclusions. These tools do not always agree even if the
assessments are refined, since although the risk estimates are close at the population level, there
are individual differences.
He stated that the crux in the older population is the competing risks of mortality that exists in
breast cancer and also other causes of mortality that can arise. It is therefore not so much about two
worlds confronting one another (there is a feeling that oncology cannot work very well with
geriatrics) but very often it is a question of sharing the information. Molecular signatures and gene
expression profiles are just as important as the information that is brought from the comprehensive
geriatric assessment. Dr Brain concluded with the importance of working together – which is the
basis of geriatric oncology.
Selecting for radiation therapy
Dr Brain’s talk was followed by a presentation given by Philip Poortmans, Professor of Radiation
Oncology, until very recently Radboud University, The Netherlands (since 1 March Institut Curie,
Paris), Past-President of the European Society for Radiotherapy and Oncology (ESTRO) and
President-Elect of the European CanCer Organisation (ECCO), on the topic of ‘Selecting for radiation
therapy’.
Professor Poortmans began by talking about life expectancy. Life expectancy in years has increased
with Australia having been in the lead for the past several years. Expectations have been beaten
continually – the line on the life expectancy graph continues to go up [18]. This fact holds a lot of
importance for the patients focussed on in this symposium. How do you define an ‘old patient’?
What is their life expectancy? Professor Poortmans highlighted that life expectancy at birth is very
different to the actual life expectancy that an individual has later on in life.
Although in England and Wales, a woman aged 65 is expected to reach roughly around the age of 93,
we are still not doing too well – since for patients above the age of 70 years, the relative survival up
to 10 years after diagnosis is decreasing [19]. There has been a little improvement in this over the
last few decades, but there is still quite some way to go.
We were then asked – ‘what is the role of radiation therapy in general in breast cancer?’ After breast
conserving therapy, the effect of radiation therapy in patients with no involved axillary lymph nodes
results in a ‘any first recurrence’ rate at 10 years decrease by 15.4% with a slight 3.3% influence on
breast cancer related mortality at 15 years. For every 5 ‘any recurrences’ prevented at 10 years, you
have 1 breast cancer related death less at 15 years [20].
Professor Poortmans then displayed data showing that if you take patients with involved lymph
nodes, the effect is slightly higher –21.2%, and the effect on breast cancer related mortality is more
impressive with 8.5%. Thereby, here only 2.5 ‘any recurrences’ need to be prevented with radiation
therapy to have 1 breast cancer related death less at 15 years [20].
Many trials tested whether radiation therapy is required after tumorectomy in ‘low-risk’ older
patients, but the criteria for inclusion differed from younger age of 50 up to at least 65 years of age
depending on the trial. Professor Poortmans focussed on just the BASO II trials, as in his opinion it
gives a good insight as it had 4 trial arms: no treatment arm (so patients had no radiation therapy,
no endocrine therapy or no systemic therapy in general) after lumpectomy; radiation therapy arm;
systemic therapy arm; both treatments arm [21]. The results are clear. If no treatment at all is given,
the recurrence rate at 10 years is about 20%. If radiation or tamoxifen is given, the recurrence rate
drops to about 3% and both treatments together resulted in only 1 recurrence (therefore local
control rate was 99%).
After working more than 25 years in the Netherlands, Professor Poortmans explained that virtually
none of the patients in the above trial would get adjuvant systemic treatment according to the
Dutch Guidelines. The Netherlands is one of those countries in which more than 20% of patients do
not receive anything thank to their low recurrences risks and the thereby limited benefit of systemic
treatments that is outweighed by the side effects.
Professor Poortmans posed the question – ‘So is radiation therapy after tumorectomy always
required?’ Generally, he said that he didn’t think it is required for all patients. In the past we
accepted 1% local recurrences per year after treatment but this has gradually decreased to a
maximum of 0.5% per year. It is important to keep in mind late relapses, and also to remember that
second primary tumours can arise in both the treated and the contralateral breast. It is also
important to consider the role of systemic treatment in this.
Professor Poortmans then described to us a very interesting and specific case to illustrate that every
patient is unique and treatment really needs to be individualised.
Radiation therapy has improved a lot. There are several ways for this with opinions differing across
the USA and Europe for example [22]. Professor Poortmans proposed that we should urgently stop
thinking in terms of ‘treatment fields’ but instead think of ‘target volumes’ – requiring prescriptions
including dose objectives aside constraints for organs at risk.
Respiratory control – now being widely introduced in the UK – is standard in the Netherlands for all
left-sided patients and some right-sided patients. It’s not there to decrease the movement of the
patient, but rather to increase the separation between the target and the heart so that the dose
which is ‘accidentally’ given to the heart can be decreased and the risk of complications lowered.
In a 2017 publication in Breast [23], it was demonstrated that breast conserving therapy rates had
improved. In an early pilot trial in the eighties, comparing breast conserving therapy with
mastectomy, at 10 years the local recurrence rate after breast conserving therapy was nearly 20%.
This dropped to about 10% at 10 years in the EORTC Boost no Boost Trial of the nineties. A recent
analysis done in the Young Boost Trial (2004-2011) [24]shows that there are only 1.8% locoregional
recurrences at 9 years in patients younger than 51! We were then presented with confirmatory data
from more than 37000 patients from the Dutch population based cancer registry [25].
Guidelines regarding partial breast irradiation have been published from Europe [26] and from the
USA [27]. At the same time, whole breast irradiation is evolving and in the UK FAST-Forward trial
(not yet published), the conventional UK schedule of 40 Gy and 15 fractions in 3 weeks is compared
to 27 Gy and 26 Gy in 5 fractions in just 1 week.
Professor Poortmans explained that we need to look beyond technical improvements. We also have
signatures from a molecular and genomic base – for example, the wound model has been tested in
breast, lung and gastric cancer [28,29]. In one trial testing this, high risk patients had a higher rate of
local recurrences in early breast cancer compared to the patients with the low risk signature [30].
We were shown a slide demonstrating how the side effects associated with radiation therapy in the
past have now improved– for example, less inconvenience due to shorter treatment times, less skin
toxicity etc…
In his conclusion Professor Poortmans explained that life expectancy should play a very important
role in our decision making process. We also need to define the tumour risk. The next important step
is shared decision making, including a very open discussion with patients. We were presented with
various scenarios for treatment – for example, for early stage, low risk patients with a short life
expectancy you would perhaps consider either surgery alone, endocrine therapy alone, or maybe
nothing at all, whereas for early stage, low risk patients with long life expectancy, you could consider
both surgery and radiation therapy.
Finally, Professor Poortmans described how from 40 years ago to now, the relative mortality
incidence has decreased from 1 out of 2.5 (for every 2.5. patients diagnosed at the same time, 1
died) to 1 out of 6 (for every 6 patients diagnosed, only 1 died) – this is a huge improvement. In his
opinion, de-escalating is a good thing but he suggested that it should be performed in a stepwise
manner. At present, the medical community has quite a lot of trust overall from patients, and once
that trust is lost, a lot of work will need to be done to restore it once again, therefore it’s important
to avoid making big mistakes.
The session on ‘Local and systemic therapies’ ended with the session chair opening up the floor for
questions to both speakers and after a short discussion the program moved on to a coffee break and
poster viewing.
Session 2: ‘New’ Ideas
This next session was chaired by Ruth Parks and featured a presentation and discussion, along with
the presentation of four oral abstracts.
Geriatrician in the preoperative assessment clinic
The first talk in this session was presented by Beatriz Korc-Grodzicki, Chief, Geriatrics Service,
Memorial Sloan Kettering Cancer Center, New York, USA, on the topic of ‘Geriatrician in the
preoperative assessment clinic’.
The trend in preoperative risk assessment for the older breast cancer patient is to take in to account
‘frailty’. Looking at the literature published between 1979 and 2016, under ‘frailty’ and ‘mortality’,
the number of publications over time has increased dramatically. So what is ‘frailty’? The concept of
frailty in the population of older adults that are going to be diagnosed with cancer (breast cancer or
otherwise) has varied over time and there have been multiple definitions of frailty.
Frailty is ‘a syndrome of advancing age characterised by immune dysregulation, chronic
inflammation, sarcopenia, increased cellular senescence, and a loss of resilience’. In this definition,
frailty is a syndrome of advancing age, however, not everybody that is frail is of an advanced age and
many times it can be the cancer treatment that leads to developing frailty even though those
patients aren’t part of the ‘older population’. Professor Korc-Grodzicki highlighted the most
important characteristics of frailty (clinical features), namely, decreased functional reserve,
impairment or dysregulation in multiple physiological symptoms and the reduced ability to regain
physiological homeostatsis after a stressful and destabilizing event.
We were told that frailty has been used for several years in the definition or implication of risk
assessment for outcomes in surgical patients. In a study published in 2010, it was demonstrated that
when frailty is added to risk indices such as the American Society of Anesthesiologists (ASA) index,
the Lee risk index or the Eagle risk index, the risk assessment for outcomes is improved [31].
Delegates were presented with the case of Miss A. She was advised to and decided to go for a
screening mammogram. She is an 82 year old patient with hypertension, diabetes and peripheral
neuropathy with chronic kidney disease related to her diabetes. She can walk slowly for a few blocks
and uses a cane. Her screening mammogram results in an abnormal mammogram and her final
diagnosis was T1 and 2 breast cancer. She had a 1.5 cm mass with some positive lymph nodes. After
biopsy she was noted to be triple negative and it was decided that she should have a lumpectomy
and a lymph node dissection followed by adjuvant chemotherapy and radiation therapy in the
future.
The first question to ask would be, ‘Will the patient tolerate and benefit from this treatment?’ This
question would probably need to have been asked before it was even suggested to the patient that
she should have a mammogram, and should also be asked after her diagnosis and prior to making a
treatment plan.
Professor Korc-Grodzicki highlighted the fact that not everyone would be the same. You could have a
wheelchair-bound 82-year old gentleman, living in a nursing home with multiple comorbidities,
multiple medications and completely functionally dependent, compared to an 82 year old gentleman
who has very little comorbidities, only takes one aspirin daily, is very fit and lively and is into a
variety of different physical activities. It is fair to say that the 82-year old gentleman in the nursing
home will be frail and have a general poor tolerance to treatment, in comparison to the other
gentleman who will probably have a tolerance to treatment similar to that of a middle-aged patient
[32].
Miss A falls under the category of a ‘vulnerable’ patient – in the middle and not at either extreme. So
it is necessary to have a better understanding of their individual situation in order to understand
how they will tolerate treatment. Professor Korc-Grodzicki explained that people fall into the risk of
saying a patient is ‘too old’ so they will not tolerate treatment since that patient has multiple
comorbidities and is not that mobile. However, many times, the age of the patient is in the eye of
the beholder. This can depend on the age of the physician and also on the little bit of ageism that is
around. This can lead to the risk of under-treatment and is a strong risk factor for a prognosis in
older patients.
In a study published in 2003 [33] it was shown that older women with breast cancer generally have a
later diagnosis, many times they can have an incomplete diagnosis assessment and they lack a
standardised therapeutic approach. As many as 50% of them had suboptimal treatment and this
resulted in a large excess of preventable breast cancer.
The opposite can be true if one just focusses on the cancer and not the patient. There is a possibility
of overtreatment and this can lead to unacceptable postoperative outcomes with high mortality or
persistent disability [34].
Professor Korc-Grodzicki stressed the importance of personalised assessment of the older patient,
looking not just at the chronological age of the patient, but also the life expectancy of the patient
and the functional reserve of the patient as they are at the moment of diagnosis. A nice approach to
decision making was published in the NCCN Guidelines [35] – it goes into a series of questions to
allow you to put things into perspective.
The first question is, ‘Is the patient at moderate or high risk of dying or suffering from cancer
considering his or her overall life expectancy?’
For example, if a patient diagnosed with breast cancer has end stage COPD, then the breast cancer is
probably not going to be a risk for that patient in terms of mortality or even suffering from the
cancer. For this patient the answer to this first question will be ‘no’ and they will just need to be
provided with symptom management and supportive care.
If the answer is ‘yes’, the next question to ask is, ‘Does this patient have decision-making capacity?’
Can the patient understand what the problem is? Can they understand the characteristics of
treatment and the pros and cons? Can they understand what the different treatments will
accomplish? Professor Korc-Grodzicki said that in her clinic, the first question she asks to patients
after saying ‘hello’, ‘how are you?’ and ‘pleased to meet you’ is, ‘please tell me in your own words
what is the disease that you have and what is your understanding of the treatment being offered’.
The answers received can be very surprising. Many patients do understand and are very clear;
however, some patients are so confused and cannot put the diagnosis and treatment together. This
can be related to cognitive difficulties, but many times it’s due to the fact that people become very
anxious, explanations are very quick and they are scared of asking questions.
If the patient is unable to make their own decision, then it will be necessary to obtain information
about this patient from the patient care giver, relatives or other physicians who know the patient
well.
If the patient is able to understand and make decisions with the geriatrician/surgeon/oncologist,
then the next question to ask is, ‘Are the patient’s goals and values consistent with wanting
anticancer therapy?’
Professor Korc-Grodzicki described how some patients will acknowledge that there is cancer and it
absolutely needs to come out. Others however will say that they have a wonderful life, and since the
cancer is asymptomatic, and they want their independence and quality of life, they will return
whenever symptoms come. If the answer is ‘yes, they do want the treatment to go ahead’, the next
step would be to assess for risk factors prior to going into the clinic for treatment.
Geriatricians assess risk factors using the ‘Geriatric Comprehensive Assessment’. The definition of
this has changed over time and is now, ‘A multidimensional, interdisciplinary patient evaluation that
leads to the identification of patient problems and the development of a plan for resolving these
problems’. It is an assessment that will identify problems that are usually not identified with a
history check and physical examination alone. When problems are identified, the goal is to try and
improve these prior to getting the appropriate treatment.
The geriatric assessment includes multiple domains, namely:
- Function – is the patient able to take care of themselves, what is their performance status, gait and
balance etc…
- Polypharmacy – how many prescription and non-prescription medications they take, how adherent
they are to these medications (particularly important if a patients is going to be treated with oral




- Social support – living conditions, what is the care giver situation
- Psychological state – the anxiety and the depression that comes with cancer diagnosis and
treatments
- Other geriatric syndromes – such as hearing loss or difficulties with vision. If a patient cannot hear
and their physician is unaware of it, the patient will be unable to follow recommendations, or they
may not be able to talk on the phone with a nurse when they are given a call. Vision impairment can
mean they may not be able to read instructions they are given regarding their treatment or
diagnosis.
In Professor Korc-Grodzicki’s presentation we heard that the geriatric focus is very much patient
care. The patient is at the centre and not the disease. The disease is just one more piece of the
treatment puzzle. The importance of geriatric assessment in preoperative risk assessment has been
widely published. Many papers can be found in the literature from over the last 10 years or so. One
example is the paper by Robinson et al [36] – examining 68-80 year old patients who had elective
surgery that required ICU admission. What Robinson et al discovered was that impaired cognition,
recent falls, low albumin and low haemoglobin, as well as functional dependency and increased
comorbidities are risk factors for 6-month mortality and post-discharge institutionalization.
Professor Korc-Grodzicki mentioned that in her institution, they demonstrated that patients who are
75 years or older who have major cancer surgeries that require more than one day of
hospitalisation, when they have multimorbidity, functional dependency and a history of falls, have
an increased risk for postoperative delirium, increased length of stay and discharge to rehabilitation
[37].
Returning to the case of Miss A – we were told that she decided to have a mammogram and was
referred to the clinic for geriatric assessment before going for breast cancer surgery. In addition to
the details we had already heard about Miss A, we learned that she had had two falls over the past 6
months, a 4lb weight loss over the past 6 months (that is 10% of her weight) and she had been a
smoker and had given up about 20 years prior. She lived with her husband of 50 years. Her husband
has dementia and they have one child who lives 30 miles away. The child is involved but she has her
own family, her own full time job and sees her parents maybe once every two or three weeks. Miss
A is actually the main carer for her husband. Her medication list is extensive in terms of prescription
medications and over-the-counter medications. In her physical exam she was a very shy woman,
exhibited no distress but had very poor eye contact, was very depressed. She had decreased pin-
prick sensation consistent with her PN, otherwise was normal.
After the geriatric assessment was conducted on this patient, many things became apparent. In
terms of her function – the patient was dependent in some of the basic activities of daily living. She
could walk independently in the home, and one block outside. For anything further she needed to be
with somebody and needed her cane. She required help for shopping, to prepare food, major
housework and laundry. However, she managed her own extensive medications and also her
husband’s extensive medications. Her long medication list needed to be cleaned up and simplified.
After evaluation, unintentional weight loss and depression was added to her list of comorbidities.
She was evaluated with Mini Cog for cognition evaluation and this is a very short test and her result
was abnormal – meaning that she has an increased risk of dementia or the possibility of cognitive
impairment. We were told that she had an abnormal CDT and 2 out of 3 recall.
Looking at the nutrition, social support and psychological state domains of the assessment, the
weight loss the patient had was related not only to her loss of appetite, but also the difficulty she
was experiencing in buying groceries and cooking for herself and for her husband. As the main
caregiver for her husband, her priority was to keep herself and her husband independent in the
community and living at home – she did not want to hear about moving either of them to a nursing
home. Her daughter is involved but lives far away, and Miss A has been quite depressed with her
husband’s situation, with her cancer diagnosis and had become completely overwhelmed.
Based on all of this, the geriatrician made recommendations prior to surgery.
- An adjustment and simplification of medication regimen
- A nutritional consultation
- A social worker - Professor Korc-Grodzicki mentioned that this was one of the most
important recommendations made since she will not be able to take care of herself post
surgically if she does not have help for herself and for her husband.
- Treatment of depression
- Physical therapy for unsteady gait
We were told that all this is a lot of work. It becomes very difficult for an oncologist or surgeon to do
this, as it can take an hour of their time. If the time factor was decreased, then this type of
assessment could become more possible for the everyday clinician. One way of doing this is to have
screening tools that would basically screen for the need of geriatric assessment. SIOG put a taskforce
together to review 17 different screening tests to determine which was more prognostic of an
impaired comprehensive geriatric assessment in older cancer patients. Professor Korc-Grodzicki
presented the conclusion of this work – ‘Screening tools in older cancer patients should not replace
geriatric assessment. However, in a busy clinical practice the use of a screening tool is recommended
to identify patients in need of further evaluation by geriatric assessment. No specific tool was
recommended or discouraged’ [38].
It is better to use a screening tool that takes a few minutes than not to use anything at all.
Professor Korc-Grodzicki presented the model of shared care at her institution, MSKCC for patients
before or during active cancer treatment. Hers is a geriatric service that is within a cancer centre and
for the USA this is very unusual. Outpatient and inpatient consultations are provided and everybody
that attends the geriatric clinic as a result of being referred for preoperative assessment will have
CGA. They see about 1200-1300 patients per year for preoperative assessment; every patient will be
seen by the geriatrician, a geriatric nurse and a pharmacist – this is the core group. If nutritional
therapy, physical therapy or social work is required, then they are called in person as cost
restrictions mean they cannot be available within the geriatric service 100% of the time. The
assessment has gone from being a 1-hour assessment to being a 15-minute assessment by making
the process electronic.
This is termed the ‘electronic Rapid Fitness Assessment (eRFA)’. The assessment is made of validated
questionnaires that touch on each one of the geriatric domains and the patients are advised that
they can complete it on their own, with their caregiver or a family member, or indeed the family
member/caregiver can complete it on their own if the patient is unable. If they have an email
address they can do this at home, or they can complete it in the clinic waiting area or the examining
room while they are waiting for the physician. The eRFA touches on all the CGA domains and is
basically completely patient centric. Everything is filled out by the patient with the exception of the
‘time up and go’ – this needs to be done by a nurse and takes at most 30 seconds, and the ‘cognitive
assessment’ – miniCog is used and that takes two minutes or so. The information goes to a database
that is used for research work, and the information also goes to a report that is printed. The
physician will have this report when they see the patient. Sections in the report in red are sections
that were not filled out and the physician can then question the patient as to why this section was
left blank, and the physician is able to go back and fill in these sections on behalf of the patient.
Professor Korc-Grodzicki explained that in their specific patient population, about 40% filled the
questionnaire in on their own, about 40% filled it in with their caregiver and about 20% of caregivers
filled it in alone.
Regarding the geriatric patient population, Professor Korc-Grodzicki summarised that the individual
needs an individual cancer treatment that is based not only on the cancer stage, the age of the
patient and the cancer therapeutics, but also has to include aspects such as comorbidities, organ
function, functional status, cognition, social support, psychological status, polypharmacy, finances
and also things like the culture, literacy and the spirituality of the patients. Many patients have
different thoughts about cancer and cancer care, and what this means for them and for their
families.
Once all this information is gleaned, then it is necessary to act on it. This is termed prehabilitation.
Prehabiliation is something that is being looked at in many different ways and is basically a way to
make the patient a little bit fitter before they undergo their surgical procedure. Professor Korc-
Grodzicki explained that initially, prehabilitation looked at the management of diseases – such as
optimising diabetes or cardiovascular disease, or providing smoking cessation instructions. However,
now with functional and geriatric assessments, prehabilitation looks into muscle strength, provision
of physical therapy and exercising, nutritional improvements, and emotional and psychological
support. When comparing prehabilitation with no prehabilitation, it has been shown that functional
recovery is faster with prehabilitation. Improvement in function is seen in both the preoperative and
postoperative periods [39].
A study published in 2013 looked at a tri-modal prehabilitation program in patients with a mean age
of 67 years with a mean program duration of 33 days (this could be a problem depending on the
patient; some patients with cancer cannot wait for 33 days to undergo treatment). This study
assessed the effects of 30 minute walking and breathing exercises 3 times a week, a nutritional
supplement of up to 1.2g/Kg of body weight and anxiety reduction techniques. Results
demonstrated that after 4 and 8 weeks, control patients did not reach the pre-surgical level of
physical ability, whereas prehabilitated patients regained the ability to walk farther than their
preoperative baseline [40].
Professor Korc-Grodzicki summarised her presentation with the following key points:
- Chronological age in itself is not a reason not to treat
- Frailty is a predictor of surgical outcomes in the older cancer patient
- Every older patient needs individualised evaluation to inform any cancer treatment – it has
to be patient centric
- The ideal evaluation is holistic and multidisciplinary
- Electronic versions were shown to be very helpful and well received
- Increasing the functional reserve in the preoperative period (prehabilitation) may accelerate
the postoperative functional recovery
- Any evaluation is better than no evaluation at all. Even if there is not much time whatsoever
to do an evaluation, just simply asking every patient seen to get off the examining table/get
up from the chair, walk 10 feet and sit down again – this 10-20 seconds of observation could
result in a world of information.
Professor Korc-Grodzicki ended her presentation with a quote, ‘Just as there should be no oncology
practice that does not make reference to the TNM staging system, there should be no onco-geriatric
practice that does not include frailty assessment’ [41].
Oral abstracts – A joint geriatric oncology clinic for the management of elderly women diagnosed
with breast cancer: the Brighton experience
Following Professor Korc-Grodzicki’s talk we were presented with a series of 4 oral abstracts, the
first of which was on the topic of ‘A joint geriatric oncology clinic for the management of older
women diagnosed with breast cancer: the Brighton experience’, presented by Fiammetta Ugolini
(Brighton and Sussex University Hospital, UK) [42].
By way of background information, Dr Ugolini spoke about how breast cancer incidence increases
with age and mentioned that the National Institute of Statistics has shown that the female UK
population is made up of over 20% of women aged 70 years or older. Over 30% of new diagnoses
occur in women over the age of 70 years. As has been mentioned in previous talks during this
symposium, older cancer patients are a heterogeneous group and treatment decisions should not be
made based on age alone. Dr Ugolini explained that in clinical practice life expectancies are difficult
to estimate and should not be confused with chronological age. Indeed, functional and cognitive
status may be a better indicator of the suitable therapeutic option. However, it is not easy in day-to-
day practice to carry out a comprehensive assessment in a busy diagnostic surgical clinic.
For all the above reasons, in 2015 the group at Brighton and Sussex University Hospital set up a
dedicated clinic in which selected patients could be assessed jointly by a geriatrician and a breast
surgeon. The first audit of their clinic activity aimed to look at the impact of joint assessment on the
management of breast cancer in the older frail population.
We were presented with various statistics from when the clinic was first set up in June 2015 to
October 2016. In conclusion, Dr Ugolini stated that assessment in the joint clinic resulted in more
patients receiving surgical treatment and issues that had been picked up by the focussed geriatric
assessment would have very likely not been picked up if patients had not been referred to that
clinic.
Oral abstracts – The management of breast cancer in elderly patients: a local audit
The next oral abstract was presented by Taner Shakir (Peterborough Breast Unit, UK) on the topic of,
‘The management of breast cancer in elderly patients; a local audit’ [43].
Dr Shakir and colleagues decided to evaluate their practice by looking at all the new diagnoses of
breast cancer in a 5-year period from the beginning of January 2011 to the end of December 2015
using an age cut off of 75 years.
Dr Shakir presented the results to the symposium, and in conclusion explained that after analysing
these results, it’s clear that although surgery was offered to primarily fitter patients and may offer
survival benefit, and that there were more complications in the mastectomy group – especially in
the over 90s, decisions are multifactorial and all areas spoken about throughout the symposium thus
far should certainly be applied.
Oral abstracts – Elders with breast cancer tend to delay seeking medical care and present with a later
stage
The next oral abstract was titled of ‘Elders with breast cancer tend to delay seeking medical care and
present with later stage’ [44] presented by Janice Tsang (Hong Kong Breast Cancer Registry, Hong
Kong Breast Cancer Foundation, Hong Kong SAR), speaking on behalf of the Hong Kong Breast
Cancer Foundation and the Hong Kong Breast Cancer Registry.
Dr Tsang explained that the fact that breast cancer is the most common female cancer in the UK is
also true for Hong Kong and 16-17% of all breast cancer patients were diagnosed at the age of 70 or
above [45]. It’s projected that the population of over 70’s is going to rise and the number of older
breast cancer patients will also increase over time. People from Hong Kong are actually on top of the
world in terms of longevity and the average life expectation for women is 87 years of age [46].
Dr Tsang presented data from the Hong Kong Breast Cancer Registry which is actually hosted by a
non-government, non-profit organisation and supported by the Hong Kong Breast Cancer
Foundation in the community. Altogether there were 13,265 female patients with breast cancer
diagnosed from 2006 to 2015. Among them, 861 of them were aged 70 years or above. About 73%
of patients were treated in the public sector and 27% were treated in the private sector.
Dr Tsang concluded that this was the first ever comprehensive study of local older breast cancer
patients in Hong Kong. The majority of older patients self-detected their cancers by chance or as an
incidental finding and it takes longer for patients aged 70 years old than for patients of all ages to
seek first medical consultation. This suggests an unmet need for increased breast awareness among
older patients and their caregivers. Older patients also tend to receive more conservative treatments
that have fewer side effects. Comorbidities in older patients could play a role in their treatment
choices and further studies are required to look into this point in more detail. As had been
mentioned in many of the previous talks, Dr Tsang explained that age may influence breast cancer
treatment, but it should not be the sole guiding principle and should not deter the intensity of
treatment.
Dr Tsang suggested that patients should be able to assess and choose standard medical treatment if
deemed fit. Something unique to the Chinese culture in lots of patients (even some oncologists in
China tend not to treat patients aged 70 years and above) is the misconception that they are going
to have more side effects. Yet, we know that the older population is a heterogeneous one and
should be treated as such. Thus, age should deter the intensity of standard treatment.
Oral abstracts – Potential impact of treatment on the mood of older women of primary breast cancer
The chair of Session 2, Ruth Parks from the School of Medicine, University of Nottingham, UK,
presented the final oral abstract on the topic of, ‘Potential impact of treatment on the mood of older
women of primary breast cancer’ [47].
Miss Parks began by explaining how we had heard already during the symposium thus far that breast
cancer in older women differs from their younger counterparts and we know that the treatment for
breast cancer is surgery, however, the challenges faced by the older population is very different and
can include things like comorbidity and frailty. Furthermore, the biology of breast cancer in older
women is different and their tumors are less likely to be as aggressive as those in the younger
patient, making the older population more likely to die of other causes than the breast cancer.
These points lead to the consideration of alternative treatments to surgery – for example primary
endocrine therapy, and there is growing evidence to suggest that CGA may be able to help in making
the decision as to who should be a candidate for surgery and who should receive non surgical
treatments in unclear scenarios.
Miss Parks and colleagues conducted a prospective two-center pilot study recruiting women over
the age of 70 years with newly diagnosed stage I or II breast cancer. CGA was performed at two time
points – one within 6 weeks of diagnosis and the second at 6 months post diagnosis. The CGA used a
validated, cancer-specific tool, and the group also assessed quality of life with EORTC scoring
assessments and conducted semi-structured interviews.
After presenting results, Miss Parks concluded that CGA may be helpful in deciding who should have
surgery or no surgery treatment in a select cohort. There was an observation of significant difference
in mood between surgical and nonsurgical candidates and therefore more work can be done to look
into possible mood interventions in these particular patients to improve their quality of life. The
study is ongoing, and is being expanded to three centers.
Session 3: Patients and carers
Following a short break for lunch and poster viewing, delegates reassembled for session 3. This
session began with an interview-style presentation mediated by Heather Stone (Lead Breast Care
Nurse Specialist, Royal Derby Hospital) during which 3 older breast cancer patients were interviewed
regarding their experiences since their diagnosis.
The patients were asked questions such as (paraphrased):
- Could you fill us in with what happened when you were diagnosed and what options you
were given at the time?
- At what stage were you told what treatments the doctors were going to be recommending?
One patient’s answer to this question was very interesting – the said that they were never
advised of any treatment they were going to have, but were told what they couldn’t have –
i.e. a mastectomy, since they were too old – although the doctors didn’t put it into so many
words, instead saying that it would be too involved and the operation would be about 2
hours, and with all the lymph nodes the patient had, it would take another 2-4 hours and
they wouldn’t stand up to it.
- What was the treatment option?
- Can you tell the audience what happens now with your follow-up?
- Were you given the choice of surgery?
- Do you feel that any point you could change your mind and be quite willing to explore other
options?
This patient had previously explained to the audience that they didn’t want to have surgery
although it was offered as one of the proposals at the time.
- When one of the suggested treatments for you was chemotherapy, what was going through
your mind when that was proposed?
- How did you get on with your chemotherapy?
- One patient had some news just the other week that they had some local recurrence of the
breast cancer and more chemotherapy had been suggested. When asked what their attitude
to this was they responded: ‘Fine. They can start it whenever they like. That’s how I feel’.
- At any stage of this process, have you felt like a date of birth, a number? Do you feel that
you would have been treated any differently if you were 20/30 years younger?
To this question, patient responses included, ‘I think the treatment that I’ve been given has
been 100%. I could not fault anybody for what I’ve had and it’s all been done so quick’. And,
‘it’s diagnosed and you get on with the job and that’s it,’ and ‘I have to agree. It’s been
excellent. The treatment has been fantastic.’
- Is there anything you would change apart from your diagnosis?
At this point the floor was open for questions.
One delegate asked, ‘What sort of information did you have when you were being given your
options? Was it just a talk with the doctor, or was it with the nurse or did you have other
information and how useful did you fine it?’
Patient answers included (paraphrased), ‘I didn’t read the contents of the envelope I was given at all.
And I didn’t like at that stage what I was told because it was all gloom and doom. I didn’t want to
know about it. But subsequently I’m very happy about it’, ‘I was given more information on
chemotherapy and radiotherapy – you could fill a book case. It was useful. You read it and put it
away’.
Another question posed by an audience member to a specific patient was, ‘Do you feel that because
you were under investigations for other things that were going on, do you feel that influenced your
decision about the diagnosis and the treatment thereafter for the breast cancer?’
This patient explained (paraphrased), ‘No, I don’t think so. It’s just something I’ve had in my mind for
years. I have had surgery but not for cancer. Operations – I just go ahead with it as you do, but with
cancer I’ve always had this feeling that once you cut it spreads and I am firmly convinced of it. And so
I would never accept surgery. I don’t know what goes on afterwards and I don’t know how I will finish
up, but I don’t want surgery.’
The patient had spoken to her doctor about this and they were well aware of how she felt.
Another important question was regarding the cost of care.
One patient answered that altogether the cost of a taxi to the hospital and back was about £13 and
had to make about one trip every three weeks when on chemotherapy and had to go in everyday
when undergoing radiation therapy, and the cost therefore mounts up.
Other cost related issues that came up were the cost of parking and time taken off work by
relatives/carers.
One of the final questions asked by the audience was ‘At the time that you had the diagnosis of
breast cancer and you were going to look forward into the future, what things were you most
worried about and what were the things that you most wanted to preserve best?’
The answers from the patients to this question were very inspiring (paraphrased).
One patient said, ‘Nothing really. At my age you don’t worry. I was so happy eventually with the care
that was taken of me I cancelled my private insurance.’
Another answered, ‘Well, I’ve always though there’s no use worrying about the past – it’s gone.
There’s no use bothering about what’s going to happen in the future, you don’t know what’s going to
happen or what’s round the corner. Live for today, Just that’s it.’
The final patient said, ‘Again, I’m quite happy with the treatment I’ve had. We couldn’t have been in
better care. You just live life for today and that’s what you’ve got to do. When I was diagnosed at
first I was supposed to have had abscesses. I was treated for 5 weeks for abscesses and it comes out
at the end it wasn’t. It was cancer. So you live for today. Do as you’ve always done. So long as I can
get to the shops every morning I don’t care a dime.’
The role of the geriatric oncology nurse
After the patient interview session, Cindy Kenis (Geriatric Oncology Nurse, University Hospitals
Leuven, Belgium) presented on ‘The role of the geriatric oncology nurse’.
Dr Kenis began by saying that ‘older persons’ are a heterogeneous population. As we grow older we
become more and more different from each other. She also spoke of how ‘cancer and aging’ is the
challenge of the century. As many other speakers had already mentioned, chronological age is not
the same as the biological age. When presented with 3 people, each 30 years of age, one could
probably guess that they are all functioning in a similar way. Conversely, when three women of 85
years of age are presented – they would most probably be very different. In the clinic when you see
an older woman with a new diagnosis of breast cancer, there are so many questions you can ask
yourself:
- What does this lady do?
- Where does she come from?
- How does she function in daily living?
- How good is her memory?
- What things does she do in her free time or when she is at home?
It can be difficult to make specific treatment decisions for older patients with cancer. In daily
practice many questions can arise, such as:
- Does further diagnostic examinations have therapeutic implications in this patient? For
example, what implications does a diagnosis of dementia or other geriatric comorbidity have
for an 85 year old woman with a new diagnosis of breast cancer?
- Is the patient ‘too old’ or ‘not too old’ for therapy?
- What is her life expectancy? A women of 85 years of age and a women of 95 years of age,
both with a new diagnosis of breast cancer will have different and specific life expectancies.
- Will he or she tolerate therapy? Patients at a breast cancer clinic could be faced with
hormonal therapy, chemotherapy, radiation therapy, and now, many new therapies are
being developed such as targeted therapies and biological agents – all therapies with
potential side effects as you could have with chemotherapy.
- Has the patient enough support to maintain therapy? For example, patients with breast
cancer may have to come to the clinic for 6 weeks for radiation therapy. Can they come
every day? Have they got someone to come with them or can they come alone?
CGA is therefore the key aspect in the care of older patients and has already been for some decades,
the cornerstone of geriatric medicine. Dr Kenis explained that CGA goes about (1) identifying
patients in need of geriatric assessment and (2) evaluating those patients with geriatric screening
and geriatric assessment based on validated instruments. Based on the results of the assessment, (3)
recommendations need to be developed and these are related to the interventions that can be
planned in the care plan. The recommendations then need to be (4) implemented and (5) provision
has to be made for follow-up.
The main goal is to see if a patient is fit or frail. It is not too difficult to recognise a very fit and a very
frail patient, but we find that the majority of older patients that we see are a group in between
these two extremes.
Dr Kenis went on to talk about how this is currently being implemented in general in the world [48].
Firstly, there is the geriatric assessment ward/geriatric unit. Most hospitals have a unit where all the
patients are hospitalised and there are two different units here – the geriatric evaluation and
management unit (GEMU), and the acute care for elders (ACE) unit. Secondly there is the geriatric
consultation team (GCT) – they are very specific for patients who are not staying in a geriatric unit
and a nurse or another healthcare professional brings geriatric expertise based on CGA. Thirdly there
is the new concept of co-management. Co-management units have a very specific focus on for
example, orthogeriatric (e.g. hip fracture).
Specifically to geriatric oncology, we were told that the following three things can be observed:
- There are countries with developed geriatric oncology units
- There is the same concept as the geriatric consultation team – so a healthcare professional
brings the geriatric expertise to the oncologic in- and outpatients of the hospital
- A model like in the United States where there are comprehensive cancer centers – where
geriatric expertise is not available nearby, so they receive educational material about how to
combine geriatric expertise and integrate this in care plans for oncology patients.
There are many ways to implement everything related to CGA in daily practice and they all have
advantages and disadvantages [48]. Dr Kenis explained that the choice is very much related to very
country specific reasons and structures and there is currently no information on which model is the
best. Interaction with multidisciplinary geriatric teams is highly recommended and in all models the
role of the nurse and their educational background is different.
The model of geriatric oncology nursing basically combines all of the concepts of oncology, geriatrics
and nursing but extends beyond traditional management of the illness and focuses on all other
aspects that are relevant for patients [49].
Dr Kenis then went through the 5 step approach to CGA step by step.
1. Screening – had already been mentioned quite a lot during the symposium. It is performed
with a screening tool and there are many different screening tools available such as G8,
Flemish version of the Triage Risk Screening Tool, Groninger Frailty Index etc… None of
these tools should replace a full geriatric assessment, but this doesn’t mean that the
screening tools don’t have any meaning. They are important and are quick and fairly simple
to use. With their combination of questions, one can get a small overview of some specific
areas. A person with a normal result on a screening tool often performs better with regards
to overall survival. They don’t have high risk for functional decline, falls and so on. If the
result with the screening tool is abnormal then a geriatric assessment will need to be
performed to explore where the specific problem areas are.
2. Geriatric assessment – this explores all the domains relevant as has already been touched
on during the symposium, namely, social support, functional status, fatigue, comorbidity,
cognition, mental health, nutritional status and geriatric syndromes, such as falls and
polypharmacy. Various tools are available to investigate these domains and it has not been
proven regarding which tool is best. The choice of which instrument to use could rely on the
local preference, aim of the tool and/or the resources present.
3. Geriatric recommendations – established based on the results of the geriatric assessment.
The geriatric oncology nurse will be available to communicate and to comment to optimize
the care/treatment plan.
4. Geriatric intervention – Dr Kenis posed the question that if you discover following the
geriatric assessment that the patient has a nutritional problem, does that mean it should be
solved before treatment starts? The answer is ‘no’. When the existence of a nutritional
problem is known, it can then be integrated in to the care plan of the patient to make sure
that something is done to target the nutritional problem from the moment the treatment of
that patient starts. Interventions can sometimes be very difficult. The results of the
assessment and recommendations could mean that other health care professionals need to
get involved – for example, the fall clinic, the memory clinic etc… For some hospitals in
Belgium, every patient that comes in with a new cancer diagnosis will always see a
psychologist, social worker and a dietician. Is this necessary? Do patients need to see all
those healthcare professionals systematically in each case? Some answer yes, some answer
no.
5. Follow-up
Why does CGA need to be performed and why is it being integrated in to daily oncology practice? Dr
Kenis explained that this assessment detects unidentified geriatric problems. Geriatric assessment
also has a prognostic and predictive value for the patient. The two main issues that are prognostic
and predictive are nutritional and functional status based on (inter)national studies. We were told
that patients who have a bad nutritional status, very often perform much worse on overall survival
and also on the experience of treatment-related toxicity and complications.
Geriatric assessment can also influence treatment decisions, not just which therapy to give, but also
whether to increase or decrease therapy intensity. The decision can sometimes be that we need to
start palliative care for example. Finally, geriatric assessment can also allow more targeted
interventions which can improve quality of life and overall survival. Targeted interventions can never
be based on the geriatric screening only. Screening will only give information about who has more of
a chance for overall survival or an increased risk for functional decline, but interventions can only be
based on the results of the assessment.
In conclusion Dr Kenis spoke of how geriatric oncology nursing is very relevant. Many nurses working
in the field of geriatric oncology have an extremely good oncology background but still need
additional education about geriatrics and other things also. An ideal model of care in geriatric
oncology nursing needs to integrate the concepts of oncology, geriatrics and nursing care. The role
of the ‘nurse’ whether specifically a geriatric oncology nurse or not, is crucial in all existing models
that are currently described in the literature. Education of oncology nurses is necessary – in the
concepts of geriatrics and they also need exposure to the use of geriatric assessment and screening
tools.
In general, Dr Kenis said that healthcare professionals need to be watchful for age related aspects as
they are important and relevant. CGA is very useful as was mentioned previously in Dr Kenis’
presentation. Overall, geriatric recommendations and interventions increase CGA effectiveness with
the final goal of improving quality of care for older patients with (breast) cancer.
Session 3 ended with a short discussion and was then adjourned for a coffee break and poster
viewing.
Session 4: Challenging areas
Selecting for breast reconstruction
The first talk for the final session of the symposium was given by Graeme Perks, Consultant Plastic
and Reconstructive Surgeon, Nottingham University Hospitals; Immediate Past President, British
Plastic Reconstructive and Aesthetic Surgeons (BAPRAS) on the topic of, ‘Selecting for breast
reconstruction’.
Mr Perks began by saying that when facing a patient in a consultation, it is important to ask ‘What
can I do to help you have more fun in life?’ He talked of how he has tried, every time he meets a
patient, to ask them what their interests and hobbies are, who they have to share a life with, what
their career has been or what the highlight of their career has been. Everybody has a story and it’s
good to ask about it.
People often think that breast reconstruction is simply about implants – however, Mr Perks
explained that he thought that the key to breast reconstruction is looking beyond the breast
implant.
There have been many issues associated with implants over the years; silicone gel implant inquiries,
TrilucentTM Breast Implant inquiries (marketed under the Freudian description that they were filled
with soya oil and therefore safe enough to eat) and titanium-coated breast implants that came from
Germany and then it was discovered that they were being put into patients and they didn’t have a
CE mark! The spinoff from that was titanium mesh which some of the surgeons would use as a part
of breast implant reconstruction that has become widely accepted as an adjunct to implant-based
reconstruction.
Mr Perks explained how implants have many problems associated with them, the biggest problem
being scar tissue that collects around the implant. The body doesn’t reject the foreign object it
recognises, but it can tightly compress the foreign object. Another problem with breast implants, is
that they don’t always stay where you put them.




It’s also important to remember that there is a patient involved in all this – it’s about an individual.
One thing a reconstructive surgeon aspires to is to try and put the patient back where possible to as
close as they were before they had the problem – this is not that easy to achieve.
Mr Perks outlined the various considerations a breast reconstructive surgeon has to think about for
each patient – namely, the tumor size, the breast volume, the relative proportions of the tumor and
the breast, what is going on in the opposite breast (for older patients it’s much more likely that the
opposite breast will need something to be done to them, because they are likely to be droopy), you
need to look at the patient as a whole and then you need to wonder about their musculoskeletal
comorbidity – have they got back pain (if the tummy is operated on, the latissimus dorsi – the core
muscles that affect the patient’s skeletal support, is altered) or shoulder pain problems? Have they
got hernias? One rule of thumb Mr Perks highlighted to delegates that he used was that, if a
patient’s tummy sticks out further than their breasts, he is very unlikely to use tissue from their
abdomen – usually because the muscle layer is too weak and they have got too much fat.
It is important to keep questioning methods and decisions and checking whether that’s the right
operation for the right patient. Mr Perks explained that some years ago, he, along with his
colleagues, looked at morbidity – where they took the flap from the tummy using the rectus-
abdominus muscle entirely as opposed to taking just the blood supply (that’s the main difference of
a TRAM flap [having to take all the muscle] and the DIEP flap [where you just take the blood
vessels]), and they showed there was no difference [50].
When beginning a reconstruction, it is the patient and their expectations/hobbies etc… that should
be taken into consideration. Mr Perks explained that he starts out asking about the person first, and
then ask them what they understand about the disease because it was necessary to build up a
picture about the patient before worrying about why they have come.
It is also important to know about vascular supply, what is going to happen with the oncologist
(chemotherapy/radiation therapy), what the surgeons are planning to do etc…. In other words – it is
necessary to know about your team.
The question is, ‘Will the process be breast reconstruction or mastectomy?’ If the breast can be
conserved, that’s definitely better, whether primary or delayed reconstruction is carried out. The
patient may well say, ‘I can’t get my head around how you reconstruct, so let me deal with the
mastectomy first and then I’ll come and talk about the reconstruction.’ Mr Perks explained that
some of the happiest patients have been patients who have decided not to have reconstruction. It is
very important to make sure the patient understands what the cost of reconstruction will be to their
bodies.
Mr Perks presented the ‘KISS’ principle – ‘Keep It Simple, Stupid!’ and explained that as breast
reconstructive surgeons, they try and apply this wherever possible, especially when it comes to
training the trainees not to get ahead of themselves and think that they are going to have
complicated, exciting surgeries – but keeping it safe and simple.
Another aspect that needs to be considered is the many costs to the patient – whether it be a
physical cost, psychological cost (not all hospitals have resident psychologists), relationship costs
(some patients may say, ‘Now, my husband won’t go near me’; you can do the best surgery in the
world, but this may affect the relationship), employment costs and financial costs.
Mr Perks once again stressed that the whole procedure needs to be about the patient and her
expectations. The patient and her partner needs to be educated in order for them to make an
informed decision and understand risks. They need to be supported by the surgeon and a specialist
nurse. Patient and partner education should also explore reconstructive options and provide them
with an understanding of the range of additional procedures that may be required.
Vascular supply can be affected by smoking, cardio-respiratory problems (Mr Perks included
diabetes here), obesity (fat is a parasite and doesn’t add any benefit to the wound healing),
problems with the skin envelope, ptosis, where you put your incision, and radiation therapy (if you
have wide-lobe excision – it causes endarteritis obliterans).
Blood supply is important. The surgeon will be faced with problems with the blood supply and
wound healing unless they bear in mind that every patient is an individual. Technology is now
available that allows a surgeon to check out the blood supply to the abdomen and when doing flap
reconstruction allows for the biggest vessel to be picked out [51]. Lord Moynihan stated that ‘The
smoother and gentler the act of surgery .... the more exquisite the wound healing.’ As a surgeon it is
necessary to be really gentle and treat the tissue with respect.
An oncologist needs to perform chemotherapy and radiation therapy prior to surgery. Questions are
being asked about whether you can give – Group 1: Immediate reconstruction and radiation therapy;
Group 2 – Delayed reconstruction after radiation therapy; Group 3 – Immediate reconstruction
without radiation therapy. This comparison is ongoing in order to see what can be done to improve
outcomes. Once the breast is irradiated, the blood supply has been damaged so it’s not a great idea
to operate on irradiated breast tissue.
Mr Perks explained that breast reconstruction includes lumpectomy, wide local excision and
implants – a cut is being made and then being sewed up again. Then there is breast conserving
therapy – perform wide local excision and reshape the breast, or local flaps can be used. Mr Perks
highlighted mammoplasty as one of the greatest advances in his opinion, allowing breast conserving
therapy to be carried out in cases where there might be poor cosmesis. Here, you can get good
access to the tumors and avoid a mastectomy and total breast reconstruction in many cases.
Mammoplasty is really good for other things also – particularly in women who’ve got droopy breasts
or large breasts – effectively, they can be given a breast reduction to give good sensation. It could
probably help with problems of radiation therapy in large breasts also.
The bottom line is to turn up to surgery fully prepared to avoid any problems in procedures.
Lipotransfer is gaining popularity. Fat is aspirated and then this can be injected in to the breast, but
there is a lot that we don’t understand here yet although work has been done in this area [52,53]. In
order for fat grafting for breast reconstruction to be carried out, you have to have a certain amount
of fat available. There have been concerns about possible promoting cancer progression, so fat
grafting is not without its problems.
Mr Perks concluded by explaining that we need to remember it’s about the patient and the patient’s
partner. Work has to be done along with the oncologist, the breast cancer surgeon and the breast
care nurse to understand from the patient what would work best for them and then really listen to
what they are saying in order to get the best outcomes.
HER2+ breast cancer in elderly
The final talk in session 4 was on the topic of ‘HER2+ breast cancer in elderly’ and was presented by
Etienne Brain (Medical Oncologist, Institut Cure, Paris, France).
Dr Brain began by explaining that HER2+ disease comprises a small segment of the breast cancer
patients, and it best exemplifies the great strides in treatment personalisation that we have seen
during the past almost 20 years. Why is HER2+ disease important?
Dr Brain went right back to the first introduction of the semi-humanised monoclonal antibody by
Roche – trastuzumab. This was progressively introduced and provided outstanding results in
combination with chemotherapy. An editorial paper published after the introduction of trastuzumab
in the adjuvant setting following ASCO 2005, stated that ‘In our opinion, there have been only two
walk-off home run oncology products or strategies in the last 20 years – ones that provided relative
reductions exceeding 50% compared with the best current care – imatinib and trastuzumab’ [54].
There is a high cost associated with this however, and all personalised medicines consistently
increase the cost in our health care system. Looking at the data in the adjuvant setting, what
trastuzumab has achieved in terms of results on progression free survival is quite remarkable as it is
quite consistent across large trials with a reduction of the risk of relapse and the risk of death.
In trials, one can see that the numbers of older patients included in the trials were a small segment -
usually between 10-15%; 16% in the HERA trail, and this doesn’t match up to the reality of what we
treat. Just because the HER2 segment is small in the older population it doesn’t mean that we should
have such a low representation in trials. Dr Brain highlighted the fact that in older patients there is
cardiac toxicity (congestive heart failure) that is observed sometimes with chemotherapy and in
particular anthracyclines – and there is certainly a higher risk with trastuzumab. One combined
analysis of various trials demonstrated that congestive heart failure cases increases with the use of
trastuzumab in the adjuvant setting and age is a factor to increasing that risk [55].
Results from analysis of the SEER database for patients 66 years of age or older, shows that during
the period of 2005-2009, the use of trastuzumab concentrates to the below 75 years age group. It is
not used very much in really older patients and the use of trastuzumab decreased with
comorbidities associated with older age [56]. There is also a risk that the officially approved 1-year
treatment schedule is not completed. Very often, these patients do not complete their whole 12
months of antibody treatment and we see up to 10% of hospitalisations due to cardiac events in the
year following the completion of treatment. This doesn’t really match the picture obtained from
clinical trial results as they do not include enough patients to get strong conclusions.
Dr Brain presented results of a paper published in the Journal of Clinical Oncology, showing the
receipt of trastuzumab among women with HER2+ breast cancer by stage and race [57]. He also
explained that when trastuzumab is used in combination with chemotherapy there are many
variations seen across the world. In the USA very often, TCH is used – makes up around 40% of cases,
trastuzumab with taxane accounts for 21% of cases, trastuzumab with single-agent chemotherapy
accounts for 14% of cases, ACTH accounts for about 9% of cases, and trastuzumab with other agents
for about 8% of cases [57]. TCH was clearly quite important here, however Dr Brain explained that
TCH use in his practice, as well as in France/Europe is quite limited.
Dr Brain also showed that TCH decreases the amount of cardiac toxicities in the adjuvant setting and
there are alternatives to the standard chemotherapy usually used in combination with trastuzumab,
and also an option for avoiding anthracyclines with a potential benefit for the older patients.
There has been a long history of different antiHER2 compounds. Lapatinib was developed as a TKI to
act on the HER2 receptor internally in tumor cells. There was a long ‘fight’ between lapatinib – the
light TKI and trastuzumab – the heavy antibody. The TKI actually has many more issues of
pharmacological interactions with co-medications which are increased in the older populations.
Dr Brain also presented a comparison between pertuzimab and T-DM1 (Kadcyla).
One of the most achieved results was the CLEOPATRA trial that looked at pertzumab + trastuzumab
+ docetaxel versus placebo + trastuzumab + docetaxel, in a metastatic first-line setting [58]. Using
two antibodies was extremely active showing a 6 month benefit in PFS leading to a new standard of
care. A specific analysis according to age shows that for a predefined threshold of 65 or 75, it
appears that two antibodies versus one does the same irrespective of age [59]. The safety profile is
different however, and there is more diarrhoea, asthenia, fatigue, decreased appetite, vomiting, and
dysgeusia (any grade) in older patients [60]. Dr Brain highlighted the importance of taking the fact
that in this large trial of 800 patients, only 19 were over 75 years of age into account.
Another possibility is using dual antibodies without chemotherapy – thus avoiding the burden of side
effects that chemotherapy brings [61]. This kind of challenge is quite important in terms of
development as older patients are more sensitive to chemotherapy. If this burden of side effects
could be skipped and only targeted therapy be used it could potentially be great. Dr Brain stated that
as a concept this is quite attractive, however it needs to be investigated and demonstrated.
The concept of dual blockade is not clear. The ALTTO DFS tried to do this using laptatinib plus
trastuzumab in an adjuvant setting and failed – there was no difference across the different curves
between dual or single blockade. A very important trial – the MARIANNE study was published last
year and compared dual blockade versus not and this also failed to see an impact of the dual
blockade [62].
The most recent results are with regards to the Phase III APHINITY study. This is a randomised trial in
an adjuvant setting – looking at the use of one or two antibodies in adjuvant chemotherapy –
trastuzumab plus pertuzumab versus trastuzumab placebo for one year. The press release reports
that it met primary criteria on DFS and this could therefore change the landscape of HER2+ disease
[63].
EORTC is looking into this as well – older patients were randomised to a strategy skipping
chemotherapy and using both antibodies versus a standard combination of dual antibodies plus
metronomic chemotherapy. This trial has completed accrual. Another Swiss trial is going to compare
exactly the same strategy – trying to skip chemotherapy and benefit the most from the dual
blockade in the adult population with some older patients. Results of both these trials can be
combined to hopefully obtain some conclusive data.
Dr Brain explained that there is a task force at SIOG which has reviewed all the literature on this
specific hot topic working for almost two years on the review (publication pending). In this they have
reached a consensus with the general message being, that these kinds of treatments which are part
of innovation and important for the older population can be used but we cannot usually extrapolate
what has been shown in trials as they have been done only on a fixed segment of the population. He
also raised the issue of cost. A hot debate in ASCO 2016 reminded the audience that the cost-
effectiveness of the HER2+ anti-HER2 treatment is only demonstrated for adjuvant treatment in
adjuvant settings for one year, and in metastatic settings for the single blockade. As soon as you
integrate the dual blockade in medicine, things change a lot and it depends on the price according to
specific countries.
It is important to introduce more older patients in future trials, as well as introducing more of a
focus on quality of life – in Dr Brain’s opinion – this is very, very important as quality of life clearly
arbitrates the choices that we make.
Conclusion – summary and ways forward
Following a discussion of the two talks in session 4, David Morgan, Consultant Clinical Oncologist
(Retired), Nottingham University Hospitals, and Symposium co-chair, presented the main concepts
that in his opinion had come through during the symposium talks.
Firstly, he explained that a number of presenters have pointed out that the question of how to
manage older patients with primary breast cancer is a big problem and the problem is getting bigger.
There are going to be more older patients – almost coming to an epidemic of older breast cancer.
These discussions, as presented in the symposium are very, very important for future practice in
oncology.
Additionally, the balance of treatment has been touched on so many times. Essentially one is
walking on a tightrope of overtreatment (harm) and undertreatment (not doing enough to combat
the cancer). Dr Morgan thought that what had been emerging during the symposium talks and what
has become clearer over time is that the question was, ‘Well, there is an issue of deciding how a
patient is going to be able to tolerate the treatment and we need to look into this.’ In the past the
question had been ‘Can we do this?’; now, the question is ‘How do we do it?’
There have been a number of presentations on the different tools that are available and have been
shown to be useful and there has been a big progress in the field of managing older patients, and
weighing up benefits and harms of treatments. Much of this has come through the involvement of
geriatricians in the process of deciding treatment for older patients. Dr Morgan explained that this is
something we should strive to do more and more in clinics – to involve geriatricians who know about
the tools that are available, how to use them and how they should be applied.
The concept of frailty was also raised during the symposium and its significance has been much more
widely appreciated in recent years. It’s a good way of describing how you are going to assess a
patient in terms of her ability to tolerate treatments that are sometimes agressive.
Dr Morgan highlighted that all speakers, and Graeme Perks in particular had raised the importance
of establishing how the patient feels about treatment, and Dr Morgan stated that he didn’t think we
could emphasise too strongly how important this is. Hearing from the patients during the patient
interview segment of the symposium demonstrated how they liked to be involved. The patients
need to be asked how they feel and physicians need to ensure that they are going along with what
they and their carers think is right.
One last important issue that Dr Morgan highlighted as coming through the conference was that
biology of the tumors is different in older patients. The very first talk in the very first symposium
many years previously was on the difference in the biology of cancer in the older patients. What is
clear is that while many cancers are aggressive and kill patients (and therefore they should not be
undertreated), in older patients, in many cases the cancer is going to ‘outlive’ the patients and these
patients will die of something other than their breast cancer. It is therefore important not to harm
their quality of life by applying treatment that is unnecessary, and this needs to be considered very
carefully when making treatment decisions.
Dr Morgan ended by thanking all those who attended the conference and also all the speakers.
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